WASHINGTON / LONDON (IT BOLTWISE) – Bayer has reached a significant milestone: The US Food and Drug Administration (FDA) has approved the new menopause drug Lynkuet. This hormone-free therapy aims to relieve moderate to severe vasomotor symptoms such as hot flashes. The US market launch is scheduled for November 2025.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
Bayer has taken a significant step in the treatment of menopausal symptoms. The US Food and Drug Administration (FDA) has approved the drug Lynkuet, which contains the active ingredient elinzanetant, for the treatment of moderate to severe vasomotor symptoms. These symptoms, which particularly include hot flashes, affect many menopausal women and can have a significant impact on quality of life.
Elinzanetant represents an innovative, hormone-free alternative to existing therapies. Current treatment approaches are often based on hormone replacement therapies, which, however, are not suitable for all patients. The FDA approval therefore marks an important step forward in the development of new treatment options for menopausal women.
The drug is already approved in several countries, including Australia, Canada, the United Kingdom and Switzerland. The decision on approval in the European Union is expected in the coming months. This international availability highlights Elinzanetant’s potential to become a global blockbuster.
Christine Roth, Executive Vice President of Global Product Strategy and Commercialization at Bayer, emphasized the importance of this approval as the first step in a new era of treatment for menopausal symptoms. The US launch is scheduled for November 2025, giving Bayer the opportunity to prepare for production and distribution.
The development of Elinzanetant is part of Bayer’s broader strategy to provide innovative solutions in women’s health. The market for menopause treatments is large and growing as more and more women look for effective and safe alternatives to traditional therapies. Experts expect the market for hormone-free treatments to grow significantly in the coming years.
Lynkuet’s FDA approval could also motivate other pharmaceutical companies to invest in research and development of hormone-free therapies. This could lead to increased competition and a wider range of treatment options for women.
Overall, the FDA’s approval of elinzanetant represents a significant advance in the treatment of menopausal symptoms. Not only does it provide a new option for patients, but it could also pave the way for further innovation in women’s health.
*Order an Amazon credit card with no annual fee with a credit limit of 2,000 euros! a‿z
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ «KI Gadgets»
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Bayer receives FDA approval for menopause drug Lynkuet”.
The post Bayer receives FDA approval for menopause drug Lynkuet appeared first on Veritas News.
